Sangamo Therapeutics, Inc. (SGMO): Price and Financial Metrics
SGMO Price/Volume Stats
| Current price | $0.50 | 52-week high | $1.78 |
| Prev. close | $0.49 | 52-week low | $0.29 |
| Day low | $0.46 | Volume | 1,005,900 |
| Day high | $0.51 | Avg. volume | 2,182,724 |
| 50-day MA | $0.79 | Dividend yield | N/A |
| 200-day MA | $0.71 | Market Cap | 104.37M |
SGMO Stock Price Chart Interactive Chart >
Sangamo Therapeutics, Inc. (SGMO) Company Bio
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. The company was founded in 1995 and is based in Richmond, California.
Latest SGMO News From Around the Web
Below are the latest news stories about SANGAMO THERAPEUTICS INC that investors may wish to consider to help them evaluate SGMO as an investment opportunity.
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite RiskyWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call TranscriptSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript November 2, 2023 Operator: Good morning, and thank you for standing by. Welcome to the Sangamo Third Quarter 2023 Teleconference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised […] |
Sangamo to cut jobs again with planned business overhaulThe gene therapy company will move headquarters and reduce its workforce by 40%, while seeking partners for its Fabry and cell therapy research. |
Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic UpdateCompany focuses on neurology-focused genomic medicine, announces restructuring and workforce reduction |
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial ResultsBRISBANE, Calif., November 01, 2023--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS |
SGMO Price Returns
| 1-mo | -19.96% |
| 3-mo | 18.06% |
| 6-mo | 7.34% |
| 1-year | -68.75% |
| 3-year | -95.86% |
| 5-year | -95.86% |
| YTD | -7.97% |
| 2023 | -82.70% |
| 2022 | -58.13% |
| 2021 | -51.94% |
| 2020 | 86.44% |
| 2019 | -27.09% |
Continue Researching SGMO
Want to see what other sources are saying about Sangamo Therapeutics Inc's financials and stock price? Try the links below:Sangamo Therapeutics Inc (SGMO) Stock Price | Nasdaq
Sangamo Therapeutics Inc (SGMO) Stock Quote, History and News - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...